About this source
- Kind
- Research
- Design
- Human clinical trial
- Population
- Postmenopausal women from the ACTIVE trial who went on to alendronate (558 who had received abaloparatide, 581 who had received placebo)
- Sample size
- 1139
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Extension of the ACTIVE trial: all participants received alendronate in the second phase, so the result reflects abaloparatide followed by alendronate, not abaloparatide alone. The hip-fracture comparison was a supplemental analysis.
Cited in
Followed by alendronate (ACTIVExtend)
Abaloparatide · Research finding
Limited
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.